Detalhe da pesquisa
1.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med
; 21(3): e1004360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502656
2.
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.
Crit Care
; 24(1): 74, 2020 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32131866
3.
Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.
J Infect Dis
; 212(1): 72-80, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25538277
4.
Manufacturers' postmarketing safety surveillance of influenza vaccine exposure in pregnancy.
Am J Obstet Gynecol
; 207(3 Suppl): S52-6, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22920060
5.
Safety and immunogenicity of an inactivated eastern equine encephalitis virus vaccine.
Vaccine
; 39(20): 2780-2790, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33888325
6.
Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Hum Vaccin
; 6(11): 906-14, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20864814
7.
Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.
Hum Vaccin
; 6(12): 1038-46, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21150279
8.
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
Hum Vaccin
; 5(1): 33-40, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-18670195
9.
Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Pediatr Infect Dis J
; 38(7): 757-764, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31194712
10.
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly.
Open Forum Infect Dis
; 6(4): ofz107, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968056
11.
Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells.
BMC Infect Dis
; 8: 104, 2008 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-18667072
12.
Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
Vaccine
; 36(43): 6424-6432, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30224199
13.
Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.
Lancet Gastroenterol Hepatol
; 3(10): 698-707, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30042064
14.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898870
15.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
Curr Opin Virol
; 17: 57-65, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827165
16.
Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
Am J Trop Med Hyg
; 69(6 Suppl): 24-31, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14740952
17.
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Am J Trop Med Hyg
; 69(6 Suppl): 48-60, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14740955
18.
A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.
Sci Transl Med
; 6(234): 234ra55, 2014 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24786323
19.
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Pediatr Infect Dis J
; 31(4): e59-65, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22418661
20.
Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
Pediatrics
; 127 Suppl 1: S16-22, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21502248